DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Idoxifene
Idoxifene
Pharmaceutical Appendix to the Tariff Schedule 2
Nontargeted Discovery of Xenobiotics in Human Urine by Maldi-Tof/Tof-Ms
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
(12) Patent Application Publication (10) Pub. No.: US 2001/0047033 A1 Taylor Et Al
Analytics for Improved Cancer Screening and Treatment John
Pure Oestrogen Antagonists for the Treatment of Advanced Breast Cancer
Recent Advances with SERM Therapies
Stembook 2018.Pdf
Idoxifene: Report of a Phase I Study in Patients with Metastatic Breast Cancer
Report on Carcinogens, Fourteenth Edition for Table of Contents, See Home Page
Customs Tariff - Schedule
Molecular Classification of Selective Oestrogen Receptor Modulators On
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0022235 A1
Appendix A: Mammalian Studies Describing the Effects of Chemicals
Membrane Transport - Biology and Therapeutics' and BACR Members' Proffered Papers
A Comparative Study of Efficacy of Letrozole Versus Clomiphene Citrate in Ovulation Induction in Patients with Polycystic Ovarian Syndrome
Raloxifene: a New Choice for Treating and Preventing Osteoporosis
Pharmaceuticals Appendix
Top View
Predicting Drug Responses by Propagating Interactions Through Text-Enhanced Drug-Gene Networks
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Future Use of Selective Estrogen Receptor Modulators and Aromatase Inhibitors I
WO 2017/180086 Al 19 October 2017 (19.10.2017) P O P C T
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Recent Advances on Liquid Chromatographic and Mass Spectrometric Analysis of Selective Estrogen Receptor Modulators (Serms) in Biological Fluids
(12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
Hormone BC Epid 05
And Doxorubicin-Sensitive And-Resistant Human
Antiproliferative Effects of Idoxifene in a Placebo-Controlled Trial in Primary Human Breast Cancer
The Discovery and Development of Selective Estrogen Receptor Modulators (Serms) for Clinical Practice
Harmonized Tariff Schedule of the United States (2006) (Rev
Alternative Strategies for the Treatment of Classical Congenital Adrenal Hyperplasia: Pitfalls and Promises
WO 2016/176666 Al 3 November 2016 (03.11.2016) P O P C T
The Role of Menopausal Hormone Therapy And
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances 2009
Treatment of Hot Flushes, Vasomotor Symptoms, and Night Sweats with Sex Steroid Precursors in Combination with Selective Estrogen Receptor Modulators
Inhibitory Effects of Idoxifene on Hepatic Fibrosis in Rats1
(12) United States Patent (10) Patent No.: US 8,206,747 B2 Zale Et Al
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Pharmaceutical Appendix to the Tariff Schedule 2
Estrogen and Homocysteine
Harmonized Tariff Schedule of the United States (2003) -- Supplement 1 Annotated for Statistical Reporting Purposes
Pharmaceuticals Appendix
(12) STANDARD PATENT (11) Application No. AU 2016256470 B2 (19) AUSTRALIAN PATENT OFFICE
(12) Patent Application Publication (10) Pub. No.: US 2007/0196433 A1 Ron Et Al
Are Nonmonotonic Dose Response Curves (Nmdrcs) Common After Estrogen Or Androgen Signaling Pathway Disruption
Endocrine Manipulation in Advanced Breast Cancer: Recent Advances with SERM Therapies
Professor Tom Connors and the Development of Novel Cancer Therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK
Effects of Estrogen on the Vascular System
Idoxifene Antagonizes Estradiol-Dependent MCF-7 Breast Cancer Xenograft Growth Through Sustained Induction of Apoptosis